Table 1. Details of traditional scores mentioned in this article.
| Scores | Author and year | Function | Based indicators | Research center | Results |
|---|---|---|---|---|---|
| PAGE-B | Papatheodoridis et al. 201619 | Score for prediction of the 5-year HCC risk in Caucasian CHB patients under entecavir/tenofovir | Age, sex, and platelets | Multicenter | c-index :0.82 |
| CU-HCC | Wong et al. 201020 | Clinical score in predicting the risk of HCC among HBV carriers | Age, albumin, bilirubin, HBV DNA, and cirrhosis | Multicenter | Negative predictive value: 97.8% and 97.3% in the training and validation cohorts |
| HCC-RESCUE | Sohn et al. 201721 | Prediction model for the development of HCC in treatment-naïve patients receiving oral antiviral treatment for CHB | Age, sex, and cirrhosis. | Multicenter | AUROCs :1 year, 3 years, and 5 years were 0.798, 0.788, and 0.817 in the testing cohort and 0.817, 0.810 and 0.809 in the validation cohort |
| ADRESS-HCC | Flemming et al. 201422 | Risk prediction model to estimate the 1-year probability of HCC | Age, diabetes, race, etiology of cirrhosis, sex, and severity of liver dysfunction | Multicenter | |
| mPAGE-B | Kim et al. 201823 | Modified PAGE-B scores to improve the predictive performance | Age, sex, platelet counts, and serum albumin levels | Multicenter | c-index 0.704 and 0.691 in the testing cohort and the validation cohort |
| THRI | Sharma et al. 201724 | Scoring system to predict HCC risk for patients with cirrhosis | Age, sex, etiology, and platelets | Multicenter | AUROC: 0.82 and 0.72 in the testing cohort and the validation cohort |
| GAG-HCC | Yuen et al. 200925 | Score to identify high-risk CHB patients for treatment and screening of HCC | Age, sex, HBV DNA levels, core promoter mutations, and cirrhosis | Multicenter | c-index: 0.77 |
| REACH-B | Yang et al. 201126 | Score to estimate the risk of developing HCC at 3, 5, and 10 years in patients with chronic hepatitis B | Sex, age, serum alanine aminotransferase concentration, HBeAg status, and serum HBV DNA level | Multicenter | AUROC: 0.902, 0.783 and 0.806 |
| REAL-B | Yang et al. 202027 | HCC risk score using routine clinical variables among a treated Asian cohort | Sex, age, alcohol use, diabetes, baseline cirrhosis, platelet count, and alpha-fetoprotein | Multicenter | AUROC: >0.80 |
AUROC, area under the receiver operating characteristic; HCC, hepatocellular carcinoma.